Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

First Contract Win for Instem Clinical

2 Jul 2013 07:00

RNS Number : 3502I
Instem plc
02 July 2013
 

2 July 2013

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

First Contract Win for Instem Clinical

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to announce its first contract win for its newly acquired ALPHADAS software. The contract consists of a high six-figure GBP perpetual licence plus implementation services, with ongoing annual support and maintenance.

ALPHADAS,the market leading, e-source data capture ("EDC") system and site automation software suite for early phase clinical studies, has been selected by a UK-based global leader in the provision of specialisedclinical services. ALPHADAS is now offered by Instem Clinical, formerly Logos Technologies, which was acquired by Instem in May 2013.

Replacing a more traditional 'form based' EDC system, ALPHADAS was selected for its ability to deliver an immediate and significant return on investment within the client's highly complex studies. ALPHADAS sources data direct from instrumentation, removes errors at source, tracks samples from collection to dispatch and enables critical real time data review. Further efficiencies are also delivered by ALPHADAS through its ability to track study subjects throughout the recruitment process, staff resourcing and site management and the provision of a fully visible audit trail.

Phil Reason, CEO of Instem plc, commented, "We are delighted to be able to announce a significant contract win for Instem Clinical, so quickly after it was established following the acquisition of Logos in May this year. A leader in their field and experiencing significant growth, the new client is currently working with some of the world's foremost pharmaceutical and research companies. This is a clear demonstration of the quality of the ALPHADAS software and the opportunity to expand Instem's market to early clinical studies."

For further information, please contact:

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Aubrey Powell

Joe Stroud

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Evans-Jones

Fiona Conroy

 

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports its clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUAWMUPWPGG
Date   Source Headline
29th May 20137:00 amRNSGlobal R&D Organisation selects Centrus & SRS
23rd May 20133:08 pmRNSResult of AGM
13th May 20137:00 amRNSAcquisition of Logos Technologies
26th Apr 20134:48 pmRNSPosting of Annual Report, Notice of AGM
23rd Apr 20136:20 pmRNSHolding(s) in Company
18th Apr 20137:00 amRNSCustomer Wins for New Provantis Release
27th Mar 20137:00 amRNSFinal Results
12th Mar 20137:00 amRNSNotice of Final Results
1st Mar 20133:25 pmRNSHolding(s) in Company
28th Feb 20137:00 amRNSUS Government Contract Win
30th Jan 20139:42 amRNSHolding(s) in Company
21st Jan 20137:00 amRNSHolding(s) in Company
10th Jan 20137:01 amRNSJOINN Laboratories China Purchases Provantis
10th Jan 20137:00 amRNSTrading Update
24th Dec 20127:00 amRNSTrading Update
18th Dec 20127:00 amRNSMulti-year Contract Extension & New Awards
3rd Dec 20127:00 amRNSCentrus Contract Win
7th Nov 20127:00 amRNSContract Win with US Government Research Agency
29th Oct 20127:00 amRNSChange of name of Nominated Adviser and Broker
19th Sep 20127:00 amRNSUnaudited Interim Results
5th Sep 20127:00 amRNSNotice of Interim Results
26th Jul 20127:00 amRNSTrading Update
25th Jul 20125:40 pmRNSHolding(s) in Company
22nd May 20123:46 pmRNSResult of AGM
8th May 201212:11 pmRNSPosting of Annual Report, Notice of AGM
24th Apr 20129:17 amRNSHolding(s) in Company
30th Mar 20124:52 pmRNSTotal Voting Rights and Capital
29th Mar 20122:49 pmRNSHolding(s) in Company
28th Mar 20127:00 amRNSFinal Results
26th Mar 20127:00 amRNSEstablishment of Instem India
8th Mar 20127:00 amRNSIssue of Equity and Director/PDMR Shareholding
20th Feb 20127:00 amRNSNotice of Final Results
9th Feb 20128:34 amRNSDirector/PDMR Shareholding
1st Feb 20129:14 amRNSAppointment of Nominated Adviser and Broker
18th Jan 20126:21 pmRNSChange of Name
9th Jan 20127:00 amRNSTrading Update
30th Nov 20113:57 pmRNSAppointment of CFO
21st Sep 20117:00 amRNSUnaudited Interim Results
10th Aug 20112:57 pmRNSNotification of Death of Director
4th May 20115:32 pmRNSPosting of Annual Report & Notice of AGM
22nd Mar 20117:00 amRNSFinal Results
4th Mar 20117:00 amRNSAcquisition of BioWisdom
19th Jan 20117:00 amRNSTrading Update
29th Oct 201011:34 amRNSTotal Voting Rights
19th Oct 20107:00 amRNSHolding(s) in Company
15th Oct 201010:38 amRNSHolding(s) in Company
13th Oct 20107:00 amRNSFirst Day of Dealings on AIM
19th Feb 20083:38 pmRNSDividend Declaration
15th Feb 200811:34 amRNSResults of GM
31st Jan 20083:28 pmRNSNotification of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.